Batavia Biosciences is proud to announce that CJ CheilJedang (Seoul, South Korea) has selected the company to advance its position in the red biotechnology field. In a press release today, CJ CheilJedang officials commented: “While many global biopharmaceutical companies are actively developing biotechnology products, Batavia is among the very few who are equipped with the…
Leiden, The Netherlands, October 28, 2021 – Batavia Biosciences is pleased to announce today that they are the manufacturing partner of IAVI’s Sudan ebolavirus vaccine candidate, rVSV∆G-SUDV-GP. The clinical trial material will be manufactured using Batavia’s highly intensified vaccine manufacturing platform, HIP-Vax®, allowing low cost of goods and a substantial reduction in time moving from…
Today, Batavia Biosciences announces the expansion of its process development facilities in Woburn, MA, United States to accommodate the increasing market demand for viral vectors. Chris Yallop, COO at Batavia Biosciences, explains: “Advances in immuno-oncology, infectious diseases and gene therapy have given rise to a profound increase in the global demand for process development and…
Leiden, The Netherlands, July 14, 2021 – Batavia Biosciences announces today that they have successfully produced vaccine material for a Phase I clinical trial of IAVI’s Lassa fever vaccine candidate, rVSV∆G-LASV-GPC. The vaccine candidate was manufactured using Batavia’s highly intensified vaccine manufacturing platform (HIP-Vax®). This platform uses the novel fixed-bed bioreactor, scale-X™, enabling the use…
Leiden, 6 July 2021 – Today, Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the SARS-CoV-2 virus. RocketVax is developing a promising second generation COVID-19…
We would like to introduce you to our newest team member: kingfisher Alec! Alec is Batavia Biosciences’ official mascot. In this post, we would like to explain how we found Alec. Why a kingfisher First, as you know, Batavia Biosciences is headquartered in the Netherlands. The motto of the founder of the Dutch monarchy, Prince…
Leiden, 3 December 2020 – KU Leuven, a leading research institution and one of the top 50 universities in the world and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of vaccines and oncology, today announce their partnership on the development of a vector based COVID-19…
Saint-Herblain, France, and Leiden, Netherlands, June 15, 2020 – Batavia Biosciences (“Batavia”) and Valneva Sweden AB, the Swedish subsidiary of Valneva SE (“Valneva”) today announced that they have entered into a collaboration agreement to accelerate market-access of a low-cost inactivated polio vaccine (IPV). This work is supported under GPEI.[1] In 2019, Batavia received a grant…
As the COVID-19 pandemic continues, we would like to update you on our business status. As a company at the forefront of epidemic preparedness, staying operational is critical as it means we can continue the valuable work we do with our clients and partners to develop treatments and cures for vaccine preventable diseases. We put…
The Bill & Melinda Gates Foundation supports international collaboration to expand global access to life-saving vaccines PHILADELPHIA — (April 29, 2020) — The Wistar Institute and Batavia Biosciences announce the launch of a strategic collaboration aimed to streamline the clinical grade manufacture and global distribution of Wistar’s rubella vaccine seed stock commonly known as RA…